BPMC Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of -34.13% compared to Blueprint Medicines's net margin of -14.12%. Blueprint Medicines's return on equity of -24.43% beat Alnylam Pharmaceuticals's return on equity of --.

Blueprint Medicines has a consensus price target of $124.90, signalling upside risk potential of 52.11%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $315.33 which suggests that it could grow by 36.8%. Given that Blueprint Medicines has higher upside potential than Alnylam Pharmaceuticals, analysts believe Blueprint Medicines is more attractive than Alnylam Pharmaceuticals.

Blueprint Medicines has a beta of 0.746, which suggesting that the stock is 25.37% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.047%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Blueprint Medicines's net income of -$50M is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 10.23x versus 13.09x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -34.13% compared to Blueprint Medicines's net margin of 16.72%. Blueprint Medicines's return on equity of -24.43% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Blueprint Medicines has a consensus price target of $124.90, signalling upside risk potential of 52.11%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.87 which suggests that it could grow by 64.69%. Given that Biomarin Pharmaceutical has higher upside potential than Blueprint Medicines, analysts believe Biomarin Pharmaceutical is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.746, which suggesting that the stock is 25.37% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.302, suggesting its less volatile than the S&P 500 by 69.812%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Blueprint Medicines's net income of -$50M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 26.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 10.23x versus 4.09x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -34.13% compared to Blueprint Medicines's net margin of 1.4%. Blueprint Medicines's return on equity of -24.43% beat Bruker's return on equity of 6.78%.

Blueprint Medicines has a consensus price target of $124.90, signalling upside risk potential of 52.11%. On the other hand Bruker has an analysts' consensus of $62.05 which suggests that it could grow by 64.42%. Given that Bruker has higher upside potential than Blueprint Medicines, analysts believe Bruker is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.746, which suggesting that the stock is 25.37% less volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.426%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.53% to investors and pays a quarterly dividend of $0.05 per share. Blueprint Medicines pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Blueprint Medicines quarterly revenues are $146.4M, which are smaller than Bruker quarterly revenues of $979.6M. Blueprint Medicines's net income of -$50M is lower than Bruker's net income of $13.7M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Bruker's PE ratio is 49.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 10.23x versus 1.68x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -34.13% compared to Blueprint Medicines's net margin of --. Blueprint Medicines's return on equity of -24.43% beat Palatin Technologies's return on equity of --.

Blueprint Medicines has a consensus price target of $124.90, signalling upside risk potential of 52.11%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Blueprint Medicines, analysts believe Palatin Technologies is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.746, which suggesting that the stock is 25.37% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $146.4M, which are larger than Palatin Technologies quarterly revenues of --. Blueprint Medicines's net income of -$50M is higher than Palatin Technologies's net income of --. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 10.23x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.